|
|
|
|
LEADER |
03192 am a22002413u 4500 |
001 |
126246 |
042 |
|
|
|a dc
|
100 |
1 |
0 |
|a Liang, Barry J
|e author
|
100 |
1 |
0 |
|a Harvard University-
|e contributor
|
700 |
1 |
0 |
|a Pigula, Michael
|e author
|
700 |
1 |
0 |
|a Baglo, Yan
|e author
|
700 |
1 |
0 |
|a Najafali, Daniel
|e author
|
700 |
1 |
0 |
|a Hasan, Tayyaba
|e author
|
700 |
1 |
0 |
|a Huang, Huang-Chiao
|e author
|
245 |
0 |
0 |
|a Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting
|
260 |
|
|
|b BioMed Central,
|c 2020-07-17T19:33:49Z.
|
856 |
|
|
|z Get fulltext
|u https://hdl.handle.net/1721.1/126246
|
520 |
|
|
|a BACKGROUND: Photoimmunotherapy involves targeted delivery of photosensitizers via an antibody conjugate (i.e., photoimmunoconjugate, PIC) followed by light activation for selective tumor killing. The trade-off between PIC selectivity and PIC uptake is a major drawback limiting the efficacy of photoimmunotherapy. Despite ample evidence showing that photoimmunotherapy is most effective when combined with chemotherapy, the design of nanocarriers to co-deliver PICs and chemotherapy drugs remains an unmet need. To overcome these challenges, we developed a novel photoimmunoconjugate-nanoliposome (PIC-Nal) comprising of three clinically used agents: anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody cetuximab (Cet), benzoporphyrin derivative (BPD) photosensitizer, and irinotecan (IRI) chemotherapy. RESULTS: The BPD photosensitizers were first tethered to Cet at a molar ratio of 6:1 using carbodiimide chemistry to form PICs. Conjugation of PICs onto nanoliposome irinotecan (Nal-IRI) was facilitated by copper-free click chemistry, which resulted in monodispersed PIC-Nal-IRI with an average size of 158.8 ± 15.6 nm. PIC-Nal-IRI is highly selective against EGFR-overexpressing epithelial ovarian cancer cells with 2- to 6-fold less accumulation in low EGFR expressing cells. Successful coupling of PIC onto Nal-IRI enhanced PIC uptake and photoimmunotherapy efficacy by up to 30% in OVCAR-5 cells. Furthermore, PIC-Nal-IRI synergistically reduced cancer viability via a unique three-way mechanism (i.e., EGFR downregulation, mitochondrial depolarization, and DNA damage). CONCLUSION: It is increasingly evident that the most effective therapies for cancer will involve combination treatments that target multiple non-overlapping pathways while minimizing side effects. Nanotechnology combined with photochemistry provides a unique opportunity to simultaneously deliver and activate multiple drugs that target all major regions of a cancer cell-plasma membrane, cytoplasm, and nucleus. PIC-Nal-IRI offers a promising strategy to overcome the selectivity-uptake trade-off, improve photoimmunotherapy efficacy, and enable multi-tier cancer targeting. Controllable drug compartmentalization, easy surface modification, and high clinical relevance collectively make PIC-Nal-IRI extremely valuable and merits further investigations in living animals.
|
520 |
|
|
|a NIH (Grant R00CA194269)
|
546 |
|
|
|a en
|
655 |
7 |
|
|a Article
|
773 |
|
|
|t 10.1186/s12951-019-0560-5
|
773 |
|
|
|t Journal of Nanobiotechnology
|